Cyagen Biosciences
Cyagen Biosciences is a private AI-enabled preclinical CRO that designs genetically engineered rodent models, humanized mouse platforms, and antibody discovery services for biopharmaceutical companies, academic researchers, and antibody therapeutics developers worldwide.
- Company typePrivate
- Founded2006
- HeadquartersSanta Clara, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Cyagen Biosciences does
Cyagen Biosciences is a privately held, AI-enabled preclinical contract research organization founded in 2006 and headquartered in Santa Clara, California, with principal research and operational facilities in Taicang, Jiangsu, China. The company specializes in the design, generation, and commercialization of genetically engineered rodent models (primarily knockout, knockin, transgenic, and humanized mice and rats), custom cell line services, virus packaging, and integrated preclinical efficacy studies across oncology, neuroscience, metabolic and cardiovascular disease, ophthalmology, and autoimmune and inflammatory disease. Its proprietary platform portfolio centers on the HUGO™ family of humanized mouse systems—HUGO-GT™ for gene therapy and oligonucleotide target validation, and the HUGO-Ab™ sub-family (HUGO-Mab™, HUGO-Light™, HUGO-Nano™, HUGO-Ab-eKO™) for fully human antibody and bispecific discovery—combined with the Turboknockout™ gene targeting technology, Cre-ESCs editing, and the Cell iGeneEditor™ / AlphaKnockout systems. More than 50,000 mouse and rat models have been delivered globally, with 16,500+ peer-reviewed SCI citations referencing Cyagen models and services, 250,000 SPF animals housed in AAALAC-accredited facilities, and a workforce exceeding 1,000 employees across 40,000+ square meters of operational footprint.
Cyagen Biosciences firmographics
Firmographics- Name
- Cyagen Biosciences
- Legal name
- Cyagen Biomodels LLC
- Website
- https://cyagen.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Cyagen Biosciences is a private AI-enabled preclinical CRO that designs genetically engineered rodent models, humanized mouse platforms, and antibody discovery services for biopharmaceutical companies, academic researchers, and antibody therapeutics developers worldwide.
- Ownership category
- akta.pro rank
Cyagen Biosciences industry classification
Industry- Product category
- Preclinical CRO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Cyagen Biosciences is headquartered
LocationHeadquarters
- HQ city
- Santa Clara
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cyagen Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Custom Genetically Engineered Animal Models: Generation of knockout, knockin, transgenic, and humanized mouse and rat models for preclinical research. Revenue generated through one-time model generation projects and repeat breeding services.
- Preclinical CRO Services: Comprehensive preclinical efficacy studies including neuroscience, oncology, ophthalmology, metabolic diseases, autoimmunity, and inflammation research services. Services include breeding, cryopreservation, phenotyping, and custom study execution.
- Virus Packaging Services: AAV, lentivirus, and adenovirus packaging for gene therapy, vaccine R&D, and gene editing applications
- Custom Cell Line Services: iPSC services, knockout/knockin cell lines, point mutation cell lines, and overexpression cell lines for genetic studies, drug screening, and therapeutic development
- Antibody Discovery Services: Fully human antibody discovery using proprietary HUGO-Ab™ platforms combined with AI-powered AbSeek™ screening for therapeutic antibody development
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Cyagen Biosciences product offering
Product offeringCore offering
Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) that generates genetically engineered mouse and rat models (knockout, knockin, transgenic, humanized) and provides preclinical research services for biopharmaceutical and academic customers. Core offerings include the HUGO series of humanized mouse platforms (HUGO-GT for gene therapy, HUGO-Ab family for antibody discovery), the MouseAtlas catalog of 18,000+ validated strains, custom cell line development, virus packaging (AAV, lentivirus, adenovirus), AI-powered antibody discovery via the AbSeek platform, and preclinical efficacy studies spanning oncology, neuroscience, metabolic, ophthalmology, and autoimmune disease areas.
Product overview
Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) providing an integrated platform of genetically engineered animal models, cell models, and preclinical research services. The core offerings include the HUGO Series humanized mouse platforms (HUGO-GT™ for gene therapy, HUGO-Ab™ family for antibody discovery including HUGO-Mab™, HUGO-Light™, HUGO-Ab-eKO™, and HUGO-Nano™), the MouseAtlas Model Library catalog of 18,000+ validated strains, and comprehensive CRO services spanning preclinical efficacy studies, virus packaging, and AI-powered discovery through the AbSeek™ computational platform. The platform supports research across oncology, metabolic diseases, autoimmunity, neuroscience, and ophthalmology with end-to-end capabilities from model generation through IND-enabling studies.
Differentiator
Problem solved
Functional benefit
Brands
- YIMA Gene: High-throughput AAV vector discovery platform subsidiary under Cyagen Group, focused on AI-driven gene therapy research and development.
- HUGO-GT™
- HUGO-Ab™
- AbSeek™
- HUGO-GT™
- Cyagen
Products and services
- HUGO-GT™ (Humanized Genomic Ortholog) Genome-wide humanized mouse platform enabling full-length human gene replacement for evaluating gene-editing therapies including antisense oligonucleotides (ASOs) and siRNAs with high translational efficiency.
- HUGO-Ab™ Fully Human Antibody Mouse Platform Integrated fully human antibody mouse platform encompassing HUGO-Mab™, HUGO-Light™, and HUGO-Nano™ for generating high-affinity human monoclonal, bispecific, and nanobody antibody candidates.
- HUGO-Mab™ Fully Human Monoclonal Antibody Mouse Fully human monoclonal antibody mouse platform for efficient generation of high-affinity human antibody candidates for therapeutic antibody discovery.
- HUGO-Light™ Fully Human Common Light Chain Mouse Fully human common light chain antibody mouse designed for bispecific antibody discovery, addressing heavy-light chain mispairing challenges.
- HUGO-Nano™ Fully Human Nanobody Mouse Fully human nanobody mouse platform generating heavy-chain-only antibodies (HCAbs) that can be engineered into next-generation bispecific antibodies for enhanced T-cell-mediated anti-tumor responses.
- HUGO-Ab-eKO™ Target Knockout Antibody Discovery Target knockout antibody discovery platform enabling enhanced antibody development through genetic modification of target genes.
- MouseAtlas Model Library Comprehensive catalog of over 18,000 validated mouse strains including knockout, knockin, conditional, and humanized models spanning multiple research areas, available for purchase and delivery.
- Genetically Engineered Animals (Custom Model Generation) Custom generation of knockout, knockin, and transgenic mouse and rat models with high genetic precision for research in genetics, pharmacology, and disease modeling.
- Virus Packaging Services AAV, lentivirus, and adenovirus packaging services for gene therapy, vaccine R&D, and gene editing applications.
- AI-Powered AAV Discovery AI-enabled adeno-associated virus (AAV) vector discovery platform for identifying novel AAV capsids with enhanced tissue targeting capability, tissue specificity, and productivity.
- AbSeek™ Intelligent Computing Platform AI-driven antibody computational platform integrating molecular dynamics simulations, generative AI models, and immunogenicity prediction algorithms for sequence generation, structural prediction, and developability optimization.
- Preclinical Efficacy CRO Services Comprehensive CRO services covering neuroscience, oncology, metabolic diseases, autoimmunity, and ophthalmology with in vivo study execution capabilities for therapeutic development.
- Custom Cell Line Services Custom induced pluripotent stem cell (iPSC), knockout, knockin, point mutation, and overexpression cell line services for genetic studies, drug screening, and therapeutic development.
- Humanized Immune System Mouse Models PBMC and HSC humanized mouse models for immuno-oncology research and human immune system studies.
- Metabolic Disease Mouse Models Disease-specific mouse models including obesity, diabetes, and cardiovascular models such as B6-hINHBE, B6-hALK7, and B6-hPCSK9.
- Oncology & Immuno-oncology Mouse Models Tumor and immuno-oncology mouse models for cancer research and therapeutic evaluation.
- hCRBN Humanized Mouse Models Humanized CRBN mouse models (Product No. C001683 and C001724) for preclinical evaluation of CRBN-recruiting PROTAC degraders and molecular glues.
Companies that use Cyagen Biosciences
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Cyagen Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature7 records
Cyagen Biosciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and secondary.
- Macau University of Science and Technology (M.U.S.T.)coreFive-year strategic partnership announced June 8, 2026, combining M.U.S.T.'s translational medicine expertise with Cyagen's AI-computational tools and fully human mouse models to advance next-generation fully human antibody discovery. The alliance aims to break through traditional bottlenecks in therapeutic antibody discovery and accelerate IND-enabling timelines through integration of AI, antibody engineering, bioinformatics, and translational drug development. Partners will jointly develop an international innovation platform for AI-driven therapeutic antibody discovery, establish advanced antibody research systems, and accelerate translation of novel antibody candidates into global development programs.
- TaconiccoreCollaboration to streamline access to preclinical mouse and rat models. Taconic and Cyagen partner to provide customers expanded access to validated preclinical models through combined model libraries and services.
- ZIP SolutionssecondaryStrategic co-marketing agreement between YIMA Gene (subsidiary under Cyagen Group) and ZIP Solutions (Barcelona, 100% affiliate of Biat Group) for gene therapy. YIMA provides AI-driven high-throughput AAV vector discovery platform while ZIP Solutions contributes innovative 'Click-Gene' tool based on proprietary split-inteins for enhanced tissue targeting and expanded genetic cargo capacity. The partnership includes joint marketing initiatives, collaborative research projects, and joint customer support.
- Neurophth Therapeutics, Inc.coreStrategic collaboration between YIMA Gene and Neurophth Therapeutics to jointly develop next-generation AAV gene therapy vectors targeting specific types of genetic ophthalmic disorders. YIMA could receive milestone payments during research and clinical phases, plus sales royalties potentially surpassing $140 million.
- HistoWizcoreStrategic co-marketing partnership announced at AALAS 2023 combining HistoWiz's automated histology and digitized pathology solutions with Cyagen's custom animal model capabilities. Provides researchers end-to-end capabilities from CAM development through tissue analysis and data digitization. Initial focus on ophthalmology, neurology, and immuno-oncology research. Both companies gain access to each other's products and services including routine tissue processing, advanced immunostaining (IHC, IF, ISH), image analysis, and pathologist consultation.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Cyagen Biosciences competitors and assessment
Company assessmentDirect peers
- Ozgene: Ozgene is an Australian transgenic and knockout rodent CRO, offering directly comparable custom model generation and Cre/lox services to Cyagen's research model business.
- Crown Bioscience: Crown Bioscience (JSR Life Sciences) provides preclinical CRO services with strong oncology and immuno-oncology focus, competing directly with Cyagen's oncology efficacy and humanized immune system mouse offerings.
- GemPharmatech: GemPharmatech is a Chinese preclinical CRO offering large-scale humanized and immunodeficient mouse models, directly competing with Cyagen's research model catalog and serving overlapping biopharma and academic customers.
- Biocytogen: Biocytogen operates RenMab/RenNano humanized mouse platforms and integrated antibody discovery services, directly competing with Cyagen's HUGO-Ab™ family and AbSeek™ AI platform for therapeutic antibody discovery customers.
- Genoway: Genoway is a European specialist in custom genetically engineered mouse and rat models, directly competing with Cyagen's Turboknockout™ and custom model generation services for academic and biotech customers.
- Taconic Biosciences: Taconic is a leading commercial provider of genetically engineered rodent models and also a Cyagen distribution partner, making it both a competitor in model provision and a route-to-market for Cyagen products.
- Ingenious Targeting Laboratory: Ingenious Targeting Laboratory is a US-based gene targeting CRO specializing in custom knockout, knockin, and conditional mouse models, directly competing with Cyagen for academic and biotech model generation contracts.
Broad incumbents
- The Jackson Laboratory: JAX is the largest nonprofit provider of genetically defined mouse models with deep academic and pharma penetration, competing with Cyagen in the research model catalog space and serving as the gold-standard reference for many institutions.
- Charles River Laboratories: Charles River is the largest preclinical CRO globally, offering end-to-end discovery and safety assessment services that compete with Cyagen's preclinical efficacy offerings while also providing alternative sourcing for genetically engineered models.
- WuXi AppTec: WuXi AppTec is a global CRO/CDMO with extensive preclinical capabilities including custom model generation, overlapping with Cyagen across research models, cell lines, and preclinical efficacy services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Cyagen Biosciences social profiles
Digital presenceCyagen Biosciences compliance and trust
Trust signalCompliance1 record
Cyagen Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyagen Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
Cyagen Biosciences subsidiaries and ownership
Company hierarchySubsidiaries2 records
Cyagen Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyagen Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyagen Biosciences
What does Cyagen Biosciences do?
Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) that generates genetically engineered mouse and rat models (knockout, knockin, transgenic, humanized) and provides preclinical research services for biopharmaceutical and academic customers. Core offerings include the HUGO series of humanized mouse platforms (HUGO-GT for gene therapy, HUGO-Ab family for antibody discovery), the MouseAtlas catalog of 18,000+ validated strains, custom cell line development, virus packaging (AAV, lentivirus, adenovirus), AI-powered antibody discovery via the AbSeek platform, and preclinical efficacy studies spanning oncology, neuroscience, metabolic, ophthalmology, and autoimmune disease areas.
Is Cyagen Biosciences a public or private company?
Cyagen Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cyagen Biosciences founded?
Cyagen Biosciences was founded in 2006. It employs 501 to 1,000 people.
Where is Cyagen Biosciences based?
Cyagen Biosciences is headquartered in Santa Clara, United States, in the North America region.
How does Cyagen Biosciences make money?
Five revenue lines are on record. Custom Genetically Engineered Animal Models are the primary driver. The others are preclinical CRO Services, virus Packaging Services, custom Cell Line Services and antibody Discovery Services.
Who are Cyagen Biosciences's main competitors?
Direct peers on record are Ozgene, Crown Bioscience, GemPharmatech, Biocytogen, Genoway, Taconic Biosciences and Ingenious Targeting Laboratory. Broad incumbents are The Jackson Laboratory, Charles River Laboratories and WuXi AppTec.
Does Cyagen Biosciences have an API?
No public API is recorded for Cyagen Biosciences.
What industry is Cyagen Biosciences in?
Cyagen Biosciences's product category is Preclinical CRO Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8071.